Voloridge Investment Management
SGMO

Voloridge Investment Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Voloridge Investment Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-248,610
Closed -$1.03M – 1601
2022
Q2 		$1.03M Sell
248,610
-84,472
-25% -$365K 0.01% 1184
2022
Q1 		$1.94M Buy
+333,082
New +$1.98M 0.01% 963
2021
Q1 		– Sell
-588,624
Closed -$9.19M – 1629
2020
Q4 		$9.19M Buy
+588,624
New +$6.9M 0.08% 288
2020
Q3 		– Sell
-38,454
Closed -$345K – 1476
2020
Q2 		$345K Buy
+38,454
New +$357K ﹤0.01% 1108
2019
Q2 		– Sell
-10,190
Closed -$97K – 1033
2019
Q1 		$97K Buy
+10,190
New +$104K ﹤0.01% 909
2018
Q2 		– Sell
-98,244
Closed -$1.87M – 584
2018
Q1 		$1.87M Sell
98,244
-109,189
-53% -$2.33M 0.04% 289
2017
Q4 		$3.4M Buy
+207,433
New +$3.09M 0.07% 256

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Voloridge Investment Management's SGMO Position: Q3 2022 in Review

Voloridge Investment Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2022, closing a stake of 248,610 shares — an estimated $1.03M sold.

Voloridge Investment Management first reported a position in SGMO in Q4 2017 and held it in 7 quarters. The position peaked at $9.19M in Q4 2020. 197 funds tracked by Wall St. Rank hold SGMO as of Q3 2022.

  • Voloridge Investment Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 248,610 SANGAMO THERAPEUTICS INC shares in Q3 2022, an estimated $1.03M.
  • Voloridge Investment Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 7 quarters.
  • Voloridge Investment Management's SANGAMO THERAPEUTICS INC position peaked at $9.19M in Q4 2020.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2022.

Based on Voloridge Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.